Key Highlights

• LSE:FAB gained approximately 7.33% on 21 July 2026, ranking among the leading gainers in the UK healthcare sector.

• Investors continued focusing on companies supporting global pharmaceutical and biotechnology research through antibody discovery and development services.

• Growing investment in biologic medicines and next-generation therapeutics continues supporting long-term healthcare sector sentiment.

• The global demand for outsourced research and development services remains an important structural growth driver.

• Investors are monitoring commercial expansion, customer wins, strategic collaborations and future revenue growth opportunities.

Why Was LSE:FAB in Focus on 21 July 2026?

Fusion Antibodies Plc attracted strong investor attention after its shares advanced approximately 7.33% during Tuesday's trading session.

Healthcare investors continue looking for specialist biotechnology companies operating in high-growth niches where long-term demand remains supported by pharmaceutical innovation.

The company's exposure to antibody discovery and therapeutic development has helped keep it on investor watchlists as biologic medicines continue becoming one of the fastest-growing areas within the global pharmaceutical industry.

As biotechnology investment continues expanding worldwide, companies providing specialist research expertise remain increasingly relevant across the healthcare ecosystem.

About Fusion Antibodies Plc

Fusion Antibodies Plc is a biotechnology company specialising in antibody discovery, engineering and optimisation services.

The company works with biotechnology and pharmaceutical organisations to support the development of antibody-based therapeutics across multiple disease areas.

Its expertise includes improving antibody characteristics, reducing development risks and supporting drug discovery programmes from early-stage research through later development phases.

As pharmaceutical companies increasingly outsource specialised research activities, service providers with deep scientific expertise continue attracting investor interest.

Why Antibody Therapeutics Continue Growing

Biologic medicines remain one of the fastest-growing segments of the pharmaceutical industry.

Several trends continue driving long-term growth.

• Rising demand for targeted therapies

• Growth in immunology treatments

• Oncology innovation

• Autoimmune disease research

• Rare disease drug development

• Precision medicine

• Biopharmaceutical investment

• Increasing outsourcing by pharmaceutical companies

Antibody therapies have become an important component of modern medicine because they offer highly targeted treatment approaches for complex diseases.

Why Did LSE:FAB Rise on 21 July 2026?

Several factors likely contributed to today's strong trading performance.

Positive biotechnology sector sentiment

Healthcare investors continued rotating into biotechnology companies with differentiated scientific capabilities.

Growing pharmaceutical research spending

Global investment into drug discovery and biologic medicines continues supporting specialist research providers.

Increasing outsourcing opportunities

Many pharmaceutical companies continue outsourcing research activities to improve efficiency and accelerate development timelines.

Momentum buying

Strong early gains encouraged additional investor participation throughout the session.

Long-term healthcare growth themes

The expanding biologics market continues supporting companies involved in antibody discovery and therapeutic development.

Healthcare Outsourcing Continues Expanding

The pharmaceutical industry increasingly relies on specialist external partners.

Key reasons include:

Access to scientific expertise

Cost efficiency

Faster development timelines

Specialised laboratory capabilities

Flexible research capacity

Innovation partnerships

This trend continues creating long-term opportunities for companies providing contract research and antibody development services.

What Investors Will Watch Next

Investors are expected to monitor several key developments.

Commercial customer growth

Expansion of customer relationships remains an important growth indicator.

New project wins

Additional research programmes could support future revenue visibility.

Strategic collaborations

Partnerships with biotechnology and pharmaceutical companies may strengthen commercial opportunities.

Operational performance

Revenue growth and margin development remain closely watched.

Scientific innovation

Continued investment in antibody technologies could enhance competitive positioning.

Global Healthcare Innovation Supports the Sector

Healthcare innovation remains one of the strongest structural investment themes globally.

Areas attracting continued investment include:

Biotechnology

Immunology

Cell therapy

Gene therapy

Antibody therapeutics

Artificial intelligence-assisted drug discovery

Precision medicine

Advanced diagnostics

Companies supporting these industries continue benefiting from expanding pharmaceutical research budgets and increasing global healthcare demand.

UK Healthcare Stocks Investors Can Also Watch

Investors following LSE:FAB are also watching several UK-listed healthcare companies operating across biotechnology, diagnostics and pharmaceutical innovation.

These include:

• LSE:IMM

• LSE:OBD

• LSE:OXB

• LSE:POLX

• LSE:GENI

• LSE:AVCT

• LSE:HVO

• LSE:AGL

• LSE:TILS

These businesses continue attracting investor attention because of their exposure to life sciences, biotechnology and healthcare innovation.

Risks Investors Continue Monitoring

Healthcare growth companies continue facing several important considerations.

Investors generally evaluate:

Commercial execution

Customer concentration

Competition

Research timelines

Funding flexibility

Market demand

Scientific differentiation

Financial performance

Monitoring these factors remains important when assessing long-term growth prospects.

Outlook

The approximately 7.33% gain recorded by LSE:FAB on 21 July 2026 reflects continued investor confidence in innovative healthcare companies serving the expanding biotechnology industry.

As biologic medicines, antibody therapeutics and pharmaceutical outsourcing continue gaining importance worldwide, Fusion Antibodies remains positioned within a market benefiting from long-term structural demand.

Future investor attention will likely remain focused on customer growth, commercial execution, strategic partnerships and continued expansion across the global biotechnology ecosystem.